Antibody Bank (Kato's Lab; Tohoku University)

Antibody Bank
(Kato's Lab; Tohoku University)

Modality

*CasMab (PDPN/ PODXL/ CD44/ EpCAM/ TROP2/ EGFR/ HER2/ HER3/ GPC1)
*mCasMab (mEGFR/ mHER2)
*pCasMab (HER2/ PDPN)
*CART (CD19/ GPC3/ HER2/ PDPN/ PODXL)
*CARM (GPC3)
*PIT (CD44v/ CD133/ dog/ EpCAM/ PDPN/ PODXL)
*RIT(PDPN/HER2)

Company (clone)

Abcam (16 mAbs)
AMab-6/ C44Mab-5/ CMab-43/ EMab-134/ GMab-r1/ H2Mab-139/ HMab-2/ KMab-1/ LpMab-7/ MMab-1/ MsMab-1/ PMab-1/ PcMab-47/ RcMab-1/ SMab-1/ WMab-1
Absolute antibody/Vector (4 mAbs)
PMab-1/ PMab-2/ PMab-292/ PMab-295
BD (21 mAbs)
C2Mab-6/ C3Mab-4/ C6Mab-9/ C39Mab-2/ C44Mab-1/ C44Mab-3/ C44Mab-6/ C44Mab-9.rMAb/ C44Mab-34/ C44Mab-94/ Cx6Mab-1/ CMab-43/ H2Mab-303 (H2Mab-304, H2Mab-307)/ EMab-134/ EMab-300/ LpMab-17/ LpMab-23/ NZ-1/ PMab-1/ RMab-3/ TgMab-2
BioLegend (7 mAbs)
C20Mab-60/ C44Mab-5/ KrMab-3/ LpMab-21/ PMab-1/ PMab-2/ YM-2
BioXCell (8 mAbs)
A4Mab-3/ C2Mab-6/ C5Mab-2/ C7Mab-2/ C8Mab-2/ Cx2Mab-1/ Cx4Mab-1/ Cx6Mab-1
CST (6 mAbs)
C44Mab-3/ C44Mab-9/ C44Mab-108/ KrMab-3/ LpMab-12/ RcMab-1
FUJIFILM WAKO (23 mAbs)
AMab-6/ CMab-43/ C44Mab-1/ C44Mab-3/ C44Mab-6/ C44Mab-9/ C44Mab-18/ C44Mab-34/ C44Mab-46/ C44Mab-94/ C44Mab-108/ EMab-134/ HMab-1/ HMab-2/ MsMab-1/ NZ-1/ NZ-1.2/ PMab-1/ PMab-38/ PcMab-47/ RMab-22/ SMab-1/ TMab-6
Hycult (3 mAbs)
LpMab-12/ LpMab-13/ LpMab-17
MCP (5 mAbs)
LpMab-3/ LpMab-7/ LpMab-9/ LpMab-12/ LpMab-21
MBL (12 mAbs)
GMab-r1/ HMab-1/ KMab-1/ KrMab-3/ MMab-1/ MsMab-2/ NZ-1.2/ PMab-1/ RcMab-1/ RMab-3/ SMab-1/ WMab-1
Merck (21 mAbs)
C8Mab-2/ C44Mab-3/ C44Mab-9/ C44Mab-108/ EpMab-16/ G4B1/ HMab-1/ LpMab-12/ LpMab-13/ LpMab-17/ LpMab-19/ LpMab-21/ MsMab-1/ NZ-1.2/ PMab-1/ PMab-2/ SMab-1/ t8E4/ TpMab-3/ TrMab-29/ TwMab-1
Novus (2 mAbs)
NZ-1.2/ PMab-1
PFI/APRO (100 mAbs)
AMab-6/ A4Mab-2/ B4Mab-7/ CMab-43/ C1Mab-6/ C2Mab-6/ C2Mab-9/ C3Mab-4/ C4Mab-1/ C5Mab-4/ C6Mab-9/ C6Mab-19/ C7Mab-2/ C8Mab-2/ C9Mab-1/ C9Mab-11/ C9Mab-24/ C10Mab-31/ C39Mab-1/ C39Mab-2/ C20Mab-60/ C44Mab-1/ C44Mab-3/ C44Mab-5/ C44Mab-6/ C44Mab-9/ C44Mab-18/ C44Mab-34/ C44Mab-94/ C44Mab-108/ C73Mab-9/ Ca1Mab-5/ Ca15Mab-1/ Ca26Mab-6/ CvMab-62/ Cx1Mab-1/ Cx2Mab-5/ Cx3Mab-4/ Cx4Mab-1/ Cx5Mab-3/ Cx6Mab-1/ Ea1Mab-30/ Ea2Mab-7/ Ea3Mab-20/ Ea4Mab-3/ Ea5Mab-7/ Ea7Mab-10/ Ea8Mab-9/ Eb2Mab-12/ Eb3Mab-11/ Eb6Mab-3/ EMab-134/ EMab-300/ EpMab-37/ G1Mab-28/ G3Mab-25/ G4B1/ G5Mab-1/ HMab-1/ HMab-2/ H2Mab-139/ H2Mab-300/ H2Mab-304/ H3Mab-17/ HisMab-1/ humCvMab-62/ KMab-1/ LpMab-12/ NZ-1/ PMab-1/ PMab-2/ PMab-32/ PMab-38/ PMab-44/ PMab-213/ PMab-219/ PMab-225/ PMab-231/ PMab-233/ PMab-235/ PMab-237/ PMab-241/ PMab-256/ PMab-265/ PMab-269/ PMab-292/ PMab-301/ PMab-314/ PcMab-47/ RdMab-2/ RdMab-13/ RdMab-20/ TmMab-1/ TmMab-2/ TMab-2/ TMab-6/ TpMab-1/ TpMab-3/ TwMab-1/ TrMab-29

Back to Antibody bank

CasMab

PDPN	Character	Application	Ref	Gene cloning	Company
anti-hPDPN mAb (LpMab-2; mouse IgG1, kappa)	CasMab; patent	IHC, WB, FACS	PDPN_review LpMab-2	done	restricted;Z
anti-hPDPN mAb (LpMab-23; mouse IgG1, kappa)		IHC, WB, FACS	LpMab-23 IHC patent	done	restricted;Z
anti-hPDPN mAb (PMab-117; rat IgM, kappa)		FACS	humPMab-117 PMab-117-mG2a Cells2022	done	restricted;Z
PDPN	Character	Application	Ref	Gene cloning	Company
anti-human PDPN mAb(chLpMab-2; human IgG1, kappa)	CasMab for human PDPN; mouse-human chimeric mAb originated from LpMab-2	IP, IHC, WB, FACS	chLpMab-2	done	restricted;Z
anti-human PDPN mAb(humLpMab-2; human IgG1, kappa)	CasMab for human PDPN; humanized mAb originated from LpMab-2	FACS		done	restricted;Z
anti-human PDPN mAb (chLpMab-23; human IgG1)	CasMab for human PDPN; mouse-human chimeric mAb originated from LpMab-23	IHC, WB, FACS	chLpMab-23	done	restricted;Z
anti-human PDPN mAb (humLpMab-23-f; human IgG1)	CasMab for human PDPN; humanized mAb originated from LpMab-23	IHC, WB, FACS	humLpMab-23-f	done	restricted;Z
anti-human PDPN mAb (PMab-117-mG2a-f; mouse IgG2a)	CasMab for human PDPN; mouse IgG2a version of PMab-117	FACS	PMab-117-mG2a	done	restricted ;Z
anti-human PDPN mAb (chPMab-117; human IgG1)	CasMab for human PDPN; mouse-human chimeric mAb originated from PMab-117	FACS		done	restricted;Z
anti-human PDPN mAb (humPMab-117-f; human IgG1)	CasMab for human PDPN; humanized mAb originated from PMab-117	FACS	humPMab-117	done	restricted;Z

Back to list

Podocalyxin	Character	Application	Ref	Gene cloning	Company
anti-PODXL mAb (PcMab-6; mouse IgG1, kappa)	anti-PODXL CasMab	FACS	PcMab-6 patent	done	restricted;Z
anti-PODXL mAb (PcMab-60; mouse IgM, kappa)	anti-PODXL CasMab	FACS	PcMab-60 epitope patent	done	restricted;Z
Podocalyxin	Character	Application	Ref	Gene cloning	Company
anti-PODXL mAb (PcMab-6-mG2a-f; mouse IgG2a)	anti-PODXL CasMab; IgG2a version of PcMab-6	FACS, ADCC/CDC	PcMab-6-mG2a-f	done	restricted;Z
anti-PODXL mAb (PcMab-6-hG1-f; human IgG1)	anti-PODXL CasMab; human IgG1 version of PcMab-6	FACS, ADCC/CDC		done	restricted;Z
anti-PODXL mAb (humPcMab-6-f; human IgG1)	CasMab for PODXL; humanized mAb originated from PcMab-6	FACS	humPcMab-6-f	done	restricted;Z
anti-PODXL mAb (60-mG2a; mouse IgG2a, kappa)	anti-PODXL CasMab; IgG2a version of PcMab-60	FACS, ADCC/CDC	60-mG2a	done	restricted;Z
anti-PODXL mAb (60-mG2a-f; mouse IgG2a, kappa)	anti-PODXL CasMab, core fucose-deficient IgG2a version of PcMab-60	FACS, ADCC/CDC, antitumor activities	60-mG2a-f	done	restricted;Z
anti-PODXL mAb (PcMab-60-hG1-f; human IgG1)	anti-PODXL CasMab; human IgG1 version of PcMab-60	FACS, ADCC/CDC		done	restricted;Z
anti-PODXL mAb (humPcMab-60; human IgG1)	anti-PODXL CasMab; humanized PcMab-60	FACS, ADCC/CDC	humPcMab-60	done	restricted;Z

Back to list

CD44s	Character	Application	Ref	Gene cloning	Company
anti-CD44s mAb (C44CasMab-1001; mouse IgM, kappa)	C44Mab-1012 for CD44s (exon-7) cossreact with mouse CD44	FACS		done	restricted;P
anti-CD44s mAb (C44CasMab-1002; mouse IgG2a, kappa)	C44Mab-1075 for CD44s (exon-7)	FACS		done	restricted;P
anti-CD44s mAb (C44CasMab-1003; mouse IgG1, kappa)	C44Mab-1095 for CD44s (exon-7)	FACS		done	restricted;P
CD44s	Character	Application	Ref	Gene cloning	Company
anti-CD44s mAb (C44Mab-1012-mG1; mouse IgG1)	Mab1 for CD44s (exon-7)	FACS		done	restricted;P
anti-CD44s mAb (C44Mab-1012-hG1; human IgG1)	Mab1 for CD44s (exon-7)	FACS		done	restricted;P
anti-CD44s mAb (C44Mab-1075-hG1; human IgG1, kappa)	human IgG1 type	FACS		done	restricted;P
anti-CD44s mAb (C44Mab-1095-mG2a; mouse IgG2a, kappa)	mouse IgG2a type	FACS		done	restricted;P
anti-CD44s mAb (C44Mab-1095-hG1; human IgG1, kappa)	human IgG1 type	FACS		done	restricted;P

Back to list

CD44v3	Character	Application	Ref	Gene cloning	Company
anti-CD44v3 mAb (C44Mab-1080; mouse IgG1, kappa)	Mab6 for CD44v3	FACS, WB, IHC		done	restricted
anti-CD44v3 mAb (C44Mab-1006; mouse IgG1, kappa)	Mab11 for CD44v3	FACS, WB, IHC		done	restricted
CD44v3	Character	Application	Ref	Gene cloning	Company
anti-CD44v3 mAb (C44Mab-1080-hG1; human IgG1, kappa)	human IgG1 type	FACS, WB, IHC		done	restricted
anti-CD44v3 mAb (C44Mab-1006-hG1; human IgG1, kappa)	human IgG1 type	FACS, WB, IHC		ongoing	restricted
CD44v5	Character	Application	Ref	Gene cloning	Company
anti-CD44v5 mAb (C44Mab-1088; mouse IgG1, kappa)	Mab8 for CD44v5	FACS, WB, IHC		done	restricted
anti-CD44v5 mAb (C44Mab-1003; mouse IgG1, kappa)	Mab12 for CD44v5	FACS, WB, IHC		done	restricted
CD44v5	Character	Application	Ref	Gene cloning	Company
anti-CD44v5 mAb (C44Mab-1088-hG1; human IgG1, kappa)	human IgG1 type	FACS, WB, IHC		done	restricted
anti-CD44v5 mAb (C44Mab-1003-hG1; human IgG1, kappa)	human IgG1 type	FACS, WB, IHC		ongoing	restricted
CD44v6 original	Character	Application	Ref	Gene cloning	Company
anti-CD44v6 mAb (C44Mab-1074; mouse IgM, kappa)	V6-1 (IgM) for CD44v6	FACS, WB, IHC		done	restricted
anti-CD44v6 mAb (C44Mab-1079; mouse IgG1, kappa)	V6-2 for CD44v6	FACS, WB, IHC		done	restricted
anti-CD44v6 mAb (C44Mab-1081; mouse IgG1, kappa)	V6-3 for CD44v6	FACS, WB, IHC		done	restricted
anti-CD44v6 mAb (C44Mab-1089; mouse IgM, kappa)	V6-4 (IgM) for CD44v6	FACS, WB, IHC		done	restricted
anti-CD44v6 mAb (C44Mab-1092; mouse IgG3, kappa)	V6-5 (IgG3) for CD44v6	FACS, WB, IHC		done	restricted
CD44v6 mouse IgG1	Character	Application	Ref	Gene cloning	Company
anti-CD44v6 mAb (C44Mab-1074-mG1; mouse IgG1, kappa)	V6-1 for CD44v6	FACS, WB, IHC		done	restricted
anti-CD44v6 mAb (C44Mab-1089-mG1; mouse IgG1, kappa)	V6-4 for CD44v6	FACS, WB, IHC		done	restricted
anti-CD44v6 mAb (C44Mab-1092-mG1; mouse IgG1, kappa)	V6-5 for CD44v6	FACS, WB, IHC		done	restricted
CD44v6 human IgG1	Character	Application	Ref	Gene cloning	Company
anti-CD44v6 mAb (C44Mab-1074-hG1; human IgG1, kappa)	V6-1 for CD44v6	FACS, WB, IHC		done	restricted
anti-CD44v6 mAb (C44Mab-1079-hG1; human IgG1, kappa)	V6-2 for CD44v6	FACS, WB, IHC		done	restricted
anti-CD44v6 mAb (C44Mab-1081-hG1; human IgG1, kappa)	V6-3 for CD44v6	FACS, WB, IHC		done	restricted
anti-CD44v6 mAb (C44Mab-1089-hG1; human IgG1, kappa)	V6-4 for CD44v6	FACS, WB, IHC		done	restricted
anti-CD44v6 mAb (C44Mab-1092-hG1; human IgG1, kappa)	V6-5 for CD44v6	FACS, WB, IHC		done	restricted
CD44v6 scFv	Character	Application	Ref	Gene cloning	Company
anti-CD44v6 mAb (C44Mab-1074; mouse IgM, kappa)	scFv from V6-1	CAR-T or TCE		done	restricted
anti-CD44v6 mAb (C44Mab-1079; mouse IgG1, kappa)	scFv from V6-2	CAR-T or TCE		done	restricted
anti-CD44v6 mAb (C44Mab-1081; mouse IgG1, kappa)	scFv from V6-3	CAR-T or TCE		done	restricted
anti-CD44v6 mAb (C44Mab-1089; mouse IgM, kappa)	scFv from V6-4	CAR-T or TCE		done	restricted
anti-CD44v6 mAb (C44Mab-1092; mouse IgG3, kappa)	scFv from V6-5	CAR-T or TCE		done	restricted
CD44v7	Character	Application	Ref	Gene cloning	Company
anti-CD44v7 mAb (C44Mab-1030; mouse IgM, kappa)	Mab4 for CD44v7	FACS, WB, IHC		done	restricted
anti-CD44v7 mAb (C44Mab-1048; mouse IgG1, kappa)	Mab5 for CD44v7	FACS, WB, IHC		done	restricted
anti-CD44v7 mAb (C44Mab-1034; mouse IgG1, kappa)	Mab10 for CD44v7	FACS, WB, IHC		done	restricted
CD44v7	Character	Application	Ref	Gene cloning	Company
anti-CD44v7 mAb (C44Mab-1030-hG1; human IgG1, kappa)	human IgG1 type	FACS, WB, IHC		done
anti-CD44v7 mAb (C44Mab-1048-hG1; human IgG1, kappa)	human IgG1 type	FACS, WB, IHC		done
anti-CD44v7 mAb (C44Mab-1034-hG1; human IgG1, kappa)	human IgG1 type	FACS, WB, IHC		ongoing

Back to list

EpCAM	Character	Application	Ref	Gene cloning	Company
anti-EpCAM mAb (EpCasMab-1; mouse IgM, kappa)	EpMab-1123 for EpCAM	FACS		done	restricted;O
anti-EpCAM mAb (EpCasMab-2; mouse IgM, kappa)	EpMab-1138 for EpCAM	FACS		done	restricted;O
anti-EpCAM mAb (EpCasMab-3; mouse IgG1, kappa)	EpMab-1147 for EpCAM	FACS		done	restricted;O
anti-EpCAM mAb (EpCasMab-4; mouse IgG1, kappa)	EpMab-1007 for EpCAM	FACS		done	restricted;O
anti-EpCAM mAb (EpCasmab-5; mouse IgG1, kappa)	EpMab-1013 for EpCAM	FACS		done	restricted;O
anti-EpCAM mAb (EpCasMab-6; mouse IgG1, kappa)	EpMab-1022 for EpCAM	FACS		done	restricted;O
anti-EpCAM mAb (EpCasMab-7; mouse IgG1, kappa)	EpMab-1069 for EpCAM	FACS		done	restricted;O
EpCAM	Character	Application	Ref	Gene cloning	Company
anti-EpCAM mAb (EpMab-1123-hG1; human IgG1, kappa)	human IgG1 type	FACS		ongoing	restricted;O
anti-EpCAM mAb (EpMab-1138-hG1; human IgG1, kappa)	human IgG1 type	FACS		ongoing	restricted;O
anti-EpCAM mAb (EpMab-1147-hG1; human IgG1, kappa)	human IgG1 type	FACS		done	restricted;O
anti-EpCAM mAb (EpMab-1007-hG1; human IgG1, kappa)	human IgG1 type	FACS		done	restricted;O
anti-EpCAM mAb (EpMab-1013-hG1; human IgG1, kappa)	human IgG1 type	FACS		done	restricted;O
anti-EpCAM mAb (EpMab-1022-hG1; human IgG1, kappa)	human IgG1 type	FACS		done	restricted;O
anti-EpCAM mAb (EpMab-1069-hG1; human IgG1, kappa)	human IgG1 type	FACS		done	restricted;O
EpCAM	Character	Application	Ref	Gene cloning	Company
anti-EpCAM mAb (EpMab-1147-mG2a; mouse IgG2a, kappa)	mouse IgG2a type	FACS		done	restricted;O
anti-EpCAM mAb (EpMab-1007-mG2a; mouse IgG2a, kappa)	mouse IgG2a type	FACS		done	restricted;O
anti-EpCAM mAb (EpMab-1013-mG2a; mouse IgG2a, kappa)	mouse IgG2a type	FACS		done	restricted;O
anti-EpCAM mAb (EpMab-1022-mG2a; mouse IgG2a, kappa)	mouse IgG2a type	FACS		done	restricted;O
anti-EpCAM mAb (EpMab-1069-mG2a; mouse IgG2a, kappa)	mouse IgG2a type	FACS		done	restricted;O

Back to list

TROP2	Character	Application	Ref	Gene cloning	Company
anti-TROP2 mAb (TCasMab-1001; mouse IgG1, kappa)	TrMab-1100 for human TROP2	FACS		done	restricted;C
anti-TROP2 mAb (TCasMab-1002; mouse IgG2a, kappa)	TrMab-1111 for human TROP2	FACS		done	restricted
anti-TROP2 mAb (TCasMab-1003; mouse IgG1, kappa)	TrMab-1148 for human TROP2	FACS		done	restricted;C
anti-TROP2 mAb (TCasMab-1004; mouse IgG2b, kappa)	TrMab-1156 for human TROP2	FACS		done	restricted;C
anti-TROP2 mAb (TCasMab-1005; mouse IgG2b, kappa)	TrMab-1172 for human TROP2	FACS		done	restricted
anti-TROP2 mAb (TCasMab-1006; mouse IgG2b, kappa)	TrMab-1174for human TROP2	FACS		done	restricted
TROP2	Character	Application	Ref	Gene cloning	Company
anti-TROP2 mAb (TrMab-1100-hG1; human IgG1, kappa)	human IgG1 type	FACS		done	restricted;C
anti-TROP2 mAb (TrMab-1111-hG1; human IgG1, kappa)	human IgG1 type	FACS		ongoing	restricted
anti-TROP2 mAb (TrMab-1148-hG1; human IgG1, kappa)	human IgG1 type	FACS		done	restricted;C
anti-TROP2 mAb (TrMab-1156-hG1; human IgG1, kappa)	human IgG1 type	FACS		done	restricted;C
anti-TROP2 mAb (TrMab-1172-hG1; human IgG1, kappa)	human IgG1 type	FACS		ongoing	restricted
anti-TROP2 mAb (TrMab-1174-hG1; human IgG1, kappa)	human IgG1 type	FACS		ongoing	restricted

Back to list

EGFR	Character	Application	Ref	Gene cloning	Company
anti-EGFR mAb (ECasMab-1001; mouse IgG1, kappa)	specific for EGFR; mAb-48; domain-4	FACS, TCE		done	restricted;O
anti-EGFR mAb (ECasMab-1002; mouse IgG1, kappa)	specific for EGFR; mAb-59; domain-3	FACS		done	restricted;O
anti-EGFR mAb (ECasMab-1003; mouse IgG1, kappa)	specific for EGFR; mAb-73; domain-1	FACS		done	restricted;O
anti-EGFR mAb (ECasMab-1004; mouse IgG1, kappa)	specific for EGFR; mAb-92; domain-1	FACS		done	restricted;O
anti-EGFR mAb (ECasMab-1005; mouse IgG1, kappa)	specific for EGFR; mAb-94; domain-1	FACS		done	restricted;O
anti-EGFR mAb (ECasMab-1006; mouse IgM, kappa)	specific for EGFR; mAb-96; domain-1	FACS		done	restricted;O
anti-EGFR mAb (ECasMab-1007; mouse IgG1, kappa)	specific for EGFR; mAb-102; domain-4	FACS		done	restricted;O
anti-EGFR mAb (ECasMab-1008; mouse IgG1, kappa)	specific for EGFR; mAb-106; domain-1	FACS		done	restricted;O
anti-EGFR mAb (ECasMab-1009; mouse IgG1, kappa)	specific for EGFR; mAb-107; domain-1	FACS, ADC		done	restricted;O
anti-EGFR mAb (ECasMab-1010; mouse IgG1, kappa)	specific for EGFR; mAb-111; domain-3	FACS		done	restricted;O
anti-EGFR mAb (ECasMab-1011; mouse IgG1, kappa)	specific for EGFR; mAb-119; domain-4	FACS		done	restricted;O
anti-EGFR mAb (ECasMab-1012; mouse IgG1, kappa)	specific for EGFR; mAb-122; domain-4	FACS		done	restricted;O
anti-EGFR mAb (ECasMab-1013; mouse IgG1, kappa)	specific for EGFR; mAb-141; domain-4	FACS		done	restricted;O
anti-EGFR mAb (ECasMab-1014; mouse IgG1, kappa)	specific for EGFR; mAb-146; domain-4	FACS		done	restricted;O
anti-EGFR mAb (ECasMab-1015; mouse IgG1, kappa)	specific for EGFR; mAb-152; domain-1	FACS		done	restricted;O
anti-EGFR mAb (ECasMab-1016; mouse IgG1, kappa)	specific for EGFR; mAb-153; domain-1	FACS		done	restricted;O
anti-EGFR mAb (ECasMab-1017; mouse IgG1, kappa)	specific for EGFR; mAb-190; domain-1	FACS		done	restricted;O
anti-EGFR mAb (ECasMab-1018; mouse IgG1, kappa)	specific for EGFR; mAb-196; domain-3	FACS		done	restricted;O
anti-EGFR mAb (ECasMab-1019; mouse IgG1, kappa)	specific for EGFR; mAb-225; domain-3	FACS		done	restricted;O
anti-EGFR mAb (ECasMab-1020; mouse IgM, kappa)	specific for EGFR; mAb-243; domain-3	FACS		done	restricted;O
EGFR	Character	Application	Ref	Gene cloning	Company
anti-EGFR mAb (ECasMab-1001-hG1; human IgG1, kappa)	specific for EGFR	FACS		done	restricted;O
anti-EGFR mAb (ECasMab-1009-hG1; human IgG1, kappa)	specific for EGFR	FACS		done	restricted;O
anti-EGFR mAb (ECasMab-1016-hG1; human IgG1, kappa)	specific for EGFR	FACS		done	restricted;O
anti-EGFR mAb (ECasMab-1020-hG1; human IgG1, kappa)	specific for EGFR	FACS		done	restricted;O

Back to list

HER2	Character	Application	Ref	Gene cloning	Company
anti-HER2 mAb (H2CasMab-1; mouse IgG1,kappa)	H2Mab-214; specific for HER2; domain-IV PCT/JP2021/043538	FACS, WB, IHC	H2Mab-214	done	restricted;0
anti-HER2 mAb (H2CasMab-2; mouse IgG1,kappa)	H2Mab-250; specific for HER2; domain-IV PCT/JP2021/043538	FACS, WB, IHC	H2Mab-250 250_in vivo 250_CDC	done	restricted;0
anti-HER2 mAb (H2Mab-1245; mouse IgG1,kappa)	Mab-34; domain-I; specific for human HER2 does not cross-react with endogenous dog HER2	FACS		done	restricted
anti-HER2 mAb (H2Mab-1268; mouse IgG1,kappa)	Mab-35; domain-I; specific for HER2 or endogenous dog HER2	FACS		done	restricted
anti-HER2 mAb (H2Mab-1278; mouse IgG1,kappa)	Mab-38; domain-I; specific for HER2 or endogenous dog HER2	FACS		done	restricted
anti-HER2 mAb (H2Mab-1180; mouse IgG1, kappa)	Mab-33; domain-III; specific for human HER2 does not cross-react with endogenous dog HER2	FACS		done	restricted
anti-HER2 mAb (H2Mab-1190; mouse IgG1,kappa)	Mab-36; domain-III; specific for HER2 does not cross-react with endogenous dog HER2	FACS		done	restricted
anti-HER2 mAb (H2Mab-1262; mouse IgG1,kappa)	Mab-37; domain-III; specific for HER2 does not cross-react with endogenous dog HER2	FACS		done	restricted
HER2	Character	Application	Ref	Gene cloning	Company
anti-HER2 mAb (H2Mab-250-mG2af; mouse IgG2a,kappa)	H2CasMab-2; specific for HER2; domain-IV	FACS, WB, IHC	H2Mab-250 250_in vivo 250_CDC	done	restricted
anti-HER2 mAb (H2Mab-250-hG1-f; human IgG1,kappa)	H2CasMab-2; specific for HER2; domain-IV	ADCC/CDC; antitumor activities	250_in vivo 250_CDC	done	restricted
anti-HER2 mAb (humH2Mab-250-f; human IgG1,kappa)	humanized H2Mab-250; H2CasMab-2; specific for HER2; domain-IV	ADCC/CDC; antitumor activities		done	restricted
anti-HER2 mAb (H2Mab-214-mG2af; mouse IgG2a,kappa)	H2CasMab-1; specific for HER2; domain-IV	FACS, WB, IHC	214-mG2a-f	done	restricted
anti-HER2 mAb (H2Mab-214-hG1; human IgG1,kappa)	H2CasMab-1; specific for HER2; domain-IV	FACS, WB, IHC		done	restricted

Back to list

HER3	Character	Application	Ref	Gene cloning	Company
anti HER3 mAb (H3CasMab-1001; mouse IgG1,kappa)	H3Mab-1059	FACS		done	restricted; P
anti HER3 mAb (H3CasMab-1002; mouse IgG1,kappa)	H3Mab-1170	FACS		done	restricted; P
HER3	Character	Application	Ref	Gene cloning	Company
anti HER3 mAb (H3Mab-1059-mG2a; mouse IgG2a,kappa)	mouse IgG2a type	FACS		done	restricted; P
anti HER3 mAb (H3Mab-1170-mG2a; mouse IgG2a,kappa)	mouse IgG2a type	FACS		done	restricted; P
HER3	Character	Application	Ref	Gene cloning	Company
anti HER3 mAb (H3Mab-1059-hG1; human IgG1,kappa)	human IgG1 type	FACS		done	restricted; P
anti HER3 mAb (H3Mab-1170-hG1; human IgG1,kappa)	human IgG1 type	FACS		done	restricted; P

Back to list

GPC1	Character	Application	Gene cloning	Company
anti GPC1 mAb (G1Mab-1013; mouse IgG1,kappa)	specific for GPC1	FACS	ongoing	restricted
anti GPC1 mAb (G1Mab-1014; mouse IgG1,kappa)	specific for GPC1	FACS	ongoing	restricted
anti GPC1 mAb (G1Mab-1072; mouse IgG1,kappa)	specific for GPC1	FACS	ongoing	restricted
anti GPC1 mAb (G1Mab-1080; mouse IgG1,kappa)	specific for GPC1	FACS	ongoing	restricted
anti GPC1 mAb (G1Mab-1085; mouse IgG1,kappa)	specific for GPC1	FACS	ongoing	restricted
anti GPC1 mAb (G1Mab-1091; mouse IgG1,kappa)	specific for GPC1	FACS	ongoing	restricted
anti GPC1 mAb (G1Mab-1095; mouse IgG1,kappa)	specific for GPC1	FACS	ongoing	restricted

Back to list

mCasMab

mouse EGFR	Character	Application	Ref	Gene cloning	Company
anti-EGFR mAb (EMab-1302; rat IgG1, lambda)	crossreact with human EGFR; domain-I semi-candidate	FACS		done	restricted
anti-EGFR mAb (EMab-1303; rat IgM, kappa)	crossreact with human EGFR; domain-III candidate	FACS		done	restricted
anti-EGFR mAb (EMab-1304; rat IgG1, lambda)	crossreact with human EGFR; domain-I semi-candidate	FACS		done	restricted
mouse EGFR	Character	Application	Ref	Gene cloning	Company
anti-EGFR mAb (EMab-1303-mG1; mouse IgG1, kappa)	mouse IgG1 type of EMab-1303	FACS		done	restricted
anti-EGFR mAb (EMab-1303-mG2a; mouse IgG2a, kappa)	mouse IgG2a type of EMab-1303	FACS		done	restricted
anti-EGFR mAb (EMab-1303-hG1; human IgG1, kappa)	humna IgG1 type of EMab-1303	FACS		done	restricted
anti-EGFR mAb (EMab-1303-scFv)	scFv of EMab-1303	FACS		done	restricted

Back to list

mouse HER2	Character	Application	Ref	Gene cloning	Company
anti-HER2 mAb (H2Mab-1301; rat IgG2a, lambda)	specific for mouse HER2; cross-react with HER2 (human; domiain-I); does not cross-react with dog HER2	FACS		done	restricted
anti-HER2 mAb (H2Mab-1316; rat IgG2a, kappa)	specific for mouse HER2; cross-react with HER2 (human; domiain-I); does not cross-react with dog HER2	FACS		done	restricted
anti-HER2 mAb (H2Mab-1319; rat IgG2a, lambda)	specific for mouse HER2; cross-react with HER2 (human; domiain-I); does not cross-react with dog HER2	FACS		done	restricted
mouse HER2 (CD340)	Character	Application	Ref	Gene cloning	Company
anti-HER2 mAb (H2Mab-1301-hG1 ;human IgG1,lambda)	hIgG1 version of H2Mab-1301; cross-react with HER2 (human)	FACS		done	restricted
anti-HER2 mAb (H2Mab-1316-hG1 ;human IgG1,kappa)	hIgG1 version of H2Mab-1316; cross-react with HER2 (human)	FACS		done	restricted
anti-HER2 mAb (H2Mab-1319-hG1 ;human IgG1,lambda)	hIgG1 version of H2Mab-1319; cross-react with HER2 (human)	FACS		done	restricted

Back to list

pCasMab

HER2	Character	Application	Gene cloning	Company
anti-HER2 mAb (H2CasMab-3; mouse IgG3,kappa)	mAb-279; specific for HER2; domain-IV PCT/JP2021/043538	FACS, WB, IHC	done	restricted;0
anti-HER2 mAb (H2CasMab-4; mouse IgG1,kappa)	mAb-280; specific for HER2; domain-IV PCT/JP2021/043538	FACS, WB, IHC	done	restricted;0
anti-HER2 mAb (H2CasMab-5; mouse IgG1,kappa)	mAb-281; specific for HER2; domain-IV PCT/JP2021/043538	FACS, WB, IHC	done	restricted;0
anti-HER2 mAb (H2CasMab-6; mouse IgG2a,kappa)	mAb-282; specific for HER2; domain-IV PCT/JP2021/043538	FACS, WB, IHC	done	restricted;0
anti-HER2 mAb (H2CasMab-7; mouse IgG1,kappa)	mAb-283; specific for HER2; domain-IV PCT/JP2021/043538	FACS, WB, IHC	done	restricted;0
anti-HER2 mAb (H2CasMab-8; mouse IgG1,kappa)	mAb-284; specific for HER2; domain-IV PCT/JP2021/043538	FACS, WB, IHC	done	restricted;0
anti-HER2 mAb (H2CasMab-9; mouse IgG3,kappa)	mAb-285; specific for HER2; domain-IV PCT/JP2021/043538	FACS, WB, IHC	done	restricted;0
anti-HER2 mAb (H2CasMab-10; mouse IgG1,kappa)	mAb-286; specific for HER2; domain-IV PCT/JP2021/043538	FACS, WB, IHC	done	restricted;0
anti-HER2 mAb (H2CasMab-11; mouse IgG1,kappa)	mAb-287; specific for HER2; domain-IV PCT/JP2021/043538	FACS, WB, IHC	done	restricted;0
anti-HER2 mAb (H2CasMab-12; mouse IgG1,kappa)	mAb-288; specific for HER2; domain-IV PCT/JP2021/043538	FACS, WB, IHC	done	restricted;0
anti-HER2 mAb (H2CasMab-13; mouse IgG1,kappa)	mAb-289; specific for HER2; domain-IV PCT/JP2021/043538	FACS, WB, IHC	done	restricted;0
anti-HER2 mAb (H2CasMab-14; mouse IgG1,kappa)	mAb-290; specific for HER2; domain-IV PCT/JP2021/043538	FACS, WB, IHC	done	restricted;0
anti-HER2 mAb (H2CasMab-15; mouse IgG3,kappa)	mAb-291; specific for HER2; domain-IV PCT/JP2021/043538	FACS, WB, IHC	done	restricted;0
anti-HER2 mAb (H2CasMab-16; mouse IgG3,kappa)	mAb-292; specific for HER2; domain-IV PCT/JP2021/043538	FACS, WB, IHC	done	restricted;0
anti-HER2 mAb (H2CasMab-17; mouse IgG3,kappa)	mAb-293; specific for HER2; domain-IV PCT/JP2021/043538	FACS, WB, IHC	done	restricted;0
anti-HER2 mAb (H2CasMab-18; mouse IgG1,kappa)	mAb-294; specific for HER2; domain-IV PCT/JP2021/043538	FACS, WB, IHC	done	restricted;0
anti-HER2 mAb (H2CasMab-19; mouse IgG1,kappa)	mAb-295; specific for HER2; domain-IV PCT/JP2021/043538	FACS, WB, IHC	done	restricted;0
anti-HER2 mAb (H2CasMab-20; mouse IgG1,kappa)	mAb-296; specific for HER2; domain-IV PCT/JP2021/043538	FACS, WB, IHC	done	restricted;0
anti-HER2 mAb (H2CasMab-21; mouse IgG2a,kappa)	mAb-297; specific for HER2; domain-IV PCT/JP2021/043538	FACS, WB, IHC	done	restricted;0
anti-HER2 mAb (H2CasMab-22; mouse IgG1,kappa)	mAb-298; specific for HER2; domain-IV PCT/JP2021/043538	FACS, WB, IHC	done	restricted;0
anti-HER2 mAb (H2CasMab-23; mouse IgG1,kappa)	mAb-299; specific for HER2; domain-IV PCT/JP2021/043538	FACS, WB, IHC	done	restricted;0

Back to list

PDPN	Character	Application	Ref	Gene cloning	Company
anti-HER2 mAb (P85Mab-1; mouse IgG1,kappa)	specific for PDPN	FACS, IHC		done	restricted

Back to list

CAR-T

CD19 original	Character	Application	Ref	Gene cloning	Company
anti-CD19 mAb (C19Mab-2; mouse IgG1,kappa)	specific for CD19; CBIS method; LN229/CD19 immunization	FACS		done
CD19 humanized	Character	Application	Ref	Gene cloning	Company
anti-CD19 mAb (humC19Mab-2; human IgG1,kappa)	specific for CD19	FACS		done
CD19 scFv	Character	Application	Ref	Gene cloning	Company
anti-CD19 mAb (humC19Mab-2 -scFv)	scFv of humanized C19Mab-2	FACS		done	iPS

Back to list

GPC3 original	Character	Application	Ref	Gene cloning	Company
anti-GPC3 mAb (G3Mab-1; mouse IgG1, kappa)	specific for human GPC3 ref: abcam	FACS		done
anti-GPC3 mAb (G3Mab-2; mouse IgM, kappa)	specific for human GPC3	FACS, WB		done
anti-GPC3 mAb (G3Mab-3; mouse IgM, kappa)	specific for human GPC3	FACS, WB		done
GPC3 humanized	Character	Application	Ref	Gene cloning	Company
anti-GPC3 mAb (humG3Mab-1; human IgG1, kappa)	specific for human GPC3	FACS		done
anti-GPC3 mAb (humG3Mab-2; human IgG1, kappa)	specific for human GPC3	FACS		done
anti-GPC3 mAb (humG3Mab-3; human IgG1, kappa)	specific for human GPC3	FACS		done
GPC3 scFv	Character	Application	Ref	Gene cloning	Company
anti-GPC3 mAb (humG3Mab-1-scFv-Fc)	specific for human GPC3	CAR-T		done
anti-GPC3 mAb (humG3Mab-2-scFv-Fc)	specific for human GPC3	CAR-T		done	iPS
anti-GPC3 mAb (humG3Mab-3-scFv-Fc)	specific for human GPC3	CAR-T		done	iPS

Back to list

HER2 original	Character	Application	Ref	Gene cloning	Company
anti-HER2 mAb (H2CasMab-2; mouse IgG1,kappa)	H2Mab-250; specific for HER2; domain-IV	FACS, WB, IHC	H2Mab-250 250_in vivo 250_CDC	done	restricted
HER2 scFv	Character	Application	Ref	Gene cloning	Company
anti-HER2 mAb (H2CasMab-2-scFv-Fc)	specific for HER2; domain-IV	CART	Cell Stem Cell	done	restricted

Back to list

PDPN original	Character	Application	Ref	Gene cloning	Company
anti-hPDPN mAb (NZ-1; rat IgG2a, lambda)	specific for human PDPN	IP, IHC, WB, FACS (Review)	NZ-1	done
anti-hPDPN mAb (LpMab-2; mouse IgG1, kappa)	CasMab	IHC, WB, FACS	Cells2022 LpMab-2 patent	done	restricted
anti-hPDPN mAb (LpMab-23; mouse IgG1, kappa)	CasMab	IHC, WB, FACS	LpMab-23 IHC patent	done	restricted
anti-hPDPN mAb (PMab-117; rat IgM, kappa)	CasMab	FACS	humPMab-117 PMab-117-mG2a Cells2022	done	restricted
PDPN humanized	Character	Application	Ref	Gene cloning	Company
anti-human PDPN mAb (NZ-27; human IgG1, lambda)	specific for human PDPN; humanized mAb originated from NZ-1	IP, IHC, WB, FACS	NZ-27	done
anti-hPDPN mAb (humLpMab-23; human IgG1, kappa)		IHC, WB, FACS	humLpMab-23-f	done	restricted
anti-hPDPN mAb (humPMab-117; human IgG1, kappa)		FACS	humPMab-117	done	restricted
PDPN scFv	Character	Application	Ref	Gene cloning	Company
anti-human PDPN mAb (NZ-1-scFv-Fc)	scFv originated from NZ-1	CART	CAR-T	done
anti-human PDPN mAb (NZ-27-scFv-Fc)	scFv originated from NZ-27	CART	CAR-T	done
anti-human PDPN mAb (LpMab-2-scFv-Fc)	CasMab for human PDPN; scFv originated from LpMab-2	CART	CAR-T	done	restricted
anti-hPDPN mAb (humLpMab-23-scFv-Fc)	CasMab for human PDPN; scFv originated from LpMab-23	CART		done	restricted
anti-hPDPN mAb (humPMab-117-scFv-Fc)	CasMab for human PDPN; scFv originated from PMab-117	CART		done	restricted

Back to list

Podocalyxin original	Character	Application	Ref	Gene cloning	Company
anti-PODXL mAb (PcMab-6; mouse IgG1, kappa)	anti-PODXL CasMab	FACS	PcMab-6 patent	done	restricted
Podocalyxin humanized	Character	Application	Ref	Gene cloning	Company
anti-PODXL mAb (humPcMab-6; human IgG1, kappa)	anti-PODXL CasMab	FACS	humPcMab-6-f	done	restricted
Podocalyxin scFv	Character	Application	Ref	Gene cloning	Company
anti-hPDPN mAb (humPcMab-6-scFv; scFv)	CasMab; scFv originated from PcMab-6	CART	CAR-T	done	restricted

Back to list

CAR-M

GPC3 original	Character	Application	Ref	Gene cloning	Company
anti-GPC3 mAb (G3Mab-4; mouse IgM, kappa)	specific for human GPC3	FACS, WB		done
GPC3 converted	Character	Application	Ref	Gene cloning	Company
anti-GPC3 mAb (G3Mab-4-mG1; mouse IgG1, kappa)	specific for human GPC3	FACS, WB		done
anti-GPC3 mAb (G3Mab-4-mG2a; mouse IgG2a, kappa)	specific for human GPC3	FACS, WB		done
GPC3 humanized	Character	Application	Ref	Gene cloning	Company
anti-GPC3 mAb (humG3Mab-4; human IgG1, kappa)	specific for human GPC3	FACS, WB		done
GPC3 scFv	Character	Application	Ref	Gene cloning	Company
anti-GPC3 mAb (humG3Mab-4-scFv-mG2a)	specific for human GPC3	FACS, WB		done	UI

Back to list

RIT

PDPN for RIT	Character	Application	Ref	Gene cloning	Collaboration
anti-human PDPN mAb (NZ-1; rat IgG2a, lambda)	specific for human PDPN	IP, IHC, WB, FACS	RIT	done	Duke
anti-human PDPN mAb (NZ-12; human IgG1, lambda)	specific for human PDPN; rat-human chimeric mAb originated from NZ-1	IP, IHC, WB, FACS	RIT	done	QST
anti-human PDPN mAb (NZ-16; human IgG1, lambda)	specific for human PDPN; rat-human chimeric mAb originated from NZ-1	IP, IHC, WB, FACS	RIT	done	QST

Back to list

HER2 for RIT	Character	Application	Ref	Gene cloning	Collaboration
anti-HER2 mAb (RIT-1; mouse IgG1, kappa)	H139-like; domain-I; specific for HER2	FACS, WB, IHC		done	E
anti-HER2 mAb (RIT-2; mouse IgG1, kappa)	H193-like; domain-II; specific for HER2	FACS		done	E
anti-HER2 mAb (RIT-3; mouse IgG1, kappa)	H181-like; domain-III; specific for HER2	FACS, IHC, WB		done	E
anti-HER2 mAb (RIT-4; mouse IgG2b, kappa)	H41-like; domain-IV; specific for HER2	FACS		done	E
HER2 chimera	Character	Application	Ref	Gene cloning	Collaboration
anti-HER2 mAb (RIT-1; human IgG1, kappa)	H139-like; domain-I; specific for HER2	FACS, WB, IHC		done	E
anti-HER2 mAb (RIT-2; human IgG1, kappa)	H193-like; domain-II; specific for HER2	FACS		done	E
anti-HER2 mAb (RIT-3; human IgG1, kappa)	H181-like; domain-III; specific for HER2	FACS, IHC, WB		done	E
anti-HER2 mAb (RIT-4; human IgG1, kappa)	H41-like; domain-IV; specific for HER2	FACS		done	E
HER2 humanized	Character	Application	Ref	Gene cloning	Collaboration
anti-HER2 mAb (humRIT-1; human IgG1, kappa)	hum_H139-like; specific for HER2 domain-I	FACS		done	E
anti-HER2 mAb (humRIT-2; human IgG1, kappa)	hum_H193-like; specific for HER2 domain-II	FACS		x	E
anti-HER2 mAb (humRIT-3; human IgG1, kappa)	hum_H181-like; specific for HER2 domain-III	FACS		done	E
anti-HER2 mAb (humRIT-4; human IgG1, kappa)	hum_H41-like; specific for HER2 domain-IV	FACS		done	E
HER2 scFv	Character	Application	Ref	Gene cloning	Collaboration
anti-HER2 mAb (humRIT-1-scFv-Fc)	scFv from humRIT-1	FACS			E
anti-HER2 mAb (humRIT-2-scFv-Fc)	scFv from humRIT-2	FACS			E
anti-HER2 mAb (humRIT-3-scFv-Fc)	scFv from humRIT-3	FACS			E
anti-HER2 mAb (humRIT-4-scFv-Fc)	scFv from humRIT-4	FACS			E

Back to list

PIT

PDPN for PIT	Character	Application	Ref	Gene cloning	Collaboration
anti-human PDPN mAb (NZ-1; rat IgG2a, lambda)	specific for human PDPN	IP, IHC, WB, FACS	Nagoya; Rowan	done	Nagoya, NIH, Rowan
anti-human PDPN mAb (NZ-1-Fab; rat IgG2a, lambda)	Fab of NZ-1	IP, IHC, WB, FACS		done	Rowan
anti-human PDPN mAb (NZ-27; human IgG1, lambda)	humanized mAb originated from NZ-1	IP, IHC, WB, FACS		done	Rowan
anti-human PDPN mAb (NC-08-hG1; human IgG1, lambda)	humanized mAb originated from NC-08	IP, IHC, WB, FACS		done	Keio/KMU
anti-human PDPN mAb (NC-08-hG2; human IgG2, lambda)	humanized mAb originated from NC-08	IP, IHC, WB, FACS		done	Keio/KMU
anti-human PDPN mAb (NC-08-hG4; human IgG4, lambda)	humanized mAb originated from NC-08	IP, IHC, WB, FACS		done	Keio/KMU
anti-human PDPN mAb (LpMab-3; mouse IgG1, kappa)	specific for human PDPN	IHC, WB, FACS		done	NIH/Keio/KMU
anti-human PDPN mAb (LpMab-7; mouse IgG1, kappa)	specific for human PDPN	IHC, WB, FACS		done	NIH
anti-human PDPN mAb (LpMab-9; mouse IgG1, kappa)	specific for human PDPN	IHC, WB, FACS		done	NIH
anti-human PDPN mAb (LpMab-10; mouse IgG3, kappa)	specific for human PDPN	IHC, WB, FACS		done	NIH
anti-human PDPN mAb (LpMab-12; mouse IgG1, kappa)	specific for human PDPN	IHC, WB, FACS		done	NIH/Keio/KMU
anti-human PDPN mAb (LpMab-13; mouse IgG1, kappa)	specific for human PDPN	IHC, WB, FACS		done	NIH
anti-human PDPN mAb (LpMab-16; mouse IgG1, kappa)	specific for human PDPN	IHC, WB, FACS		done	NIH
anti-human PDPN mAb (LpMab-17; mouse IgG1, kappa)	specific for human PDPN	IHC, WB, FACS		done	NIH
anti-human PDPN mAb (LpMab-19; mouse IgG2b, kappa)	specific for human PDPN	IHC, WB, FACS		done	NIH/Keio/KMU
anti-human PDPN mAb (LpMab-21; mouse IgG2a, kappa)	specific for human PDPN	IHC, WB, FACS		done	NIH/Keio/KMU

Back to list

PODXL for PIT	Character	Application	Gene cloning	Collaboration
anti-PODXL mAb (PcMab-47; mouse IgG1, kappa)	specific for human PODXL	FACS, WB, IHC	done	NIH
anti-PODXL mAb (PcMab-6; mouse IgG1, kappa)	anti-PODXL CasMab	FACS	done	NIH
anti-PODXL mAb (60-mG2a; mouse IgG2a, kappa)	anti-PODXL CasMab; IgG2a version of PcMab-60	FACS, ADCC/CDC	done	NIH

Back to list

EpCAM for PIT	Character	Application	Ref	Gene cloning	Collaboration
anti-EpCAM mAb (EpMab-37; mouse IgG1, kappa)	specific for EpCAM	FACS, WB, IHC		done	KMU

Back to list

CD44v for PIT	Character	Application	Gene cloning	Collaboration
anti-CD44v3 mAb (C44Mab-6; mouse IgG1, kappa)	specific for CD44v3 (oral cancer and colon cancer)	FACS, WB, IHC, ELISA	done	NIH
anti-CD44v4 mAb (C44Mab-108; mouse IgG1, kappa)	specific for CD44v4 (oral cancer)	WB, IHC, ELISA	done	NIH
anti-CD44v5 mAb (C44Mab-3; mouse IgG1, kappa)	specific for CD44v5 (pancreatic cancer)	FACS, WB, IHC, ELISA	done	NIH
anti-CD44v6 mAb (C44Mab-9; mouse IgG1, kappa)	specific for CD44v6 (colon cancer)	FACS, WB, IHC, ELISA	done	NIH
anti-CD44v7/v8 mAb (C44Mab-34; mouse IgG1, kappa)	specific for CD44v7/v8 (oral cancer)	FACS, WB, IHC, ELISA	done	NIH
anti-CD44v8 mAb (C44Mab-94; mouse IgG1, kappa)	specific for CD44v8 (gastric cancer)	FACS, WB, IHC, ELISA	done	NIH
anti-CD44v9 mAb (C44Mab-1; mouse IgG1, kappa)	specific for CD44v9 (colon cancer)	FACS, WB, IHC, ELISA	done	NIH
anti-CD44v10 mAb (C44Mab-18; mouse IgM, kappa)	specific for CD44v10 (oral cancer)	FACS, WB, IHC, ELISA	done	NIH

Back to list

CD133 for PIT	Character	Application	Ref	Gene cloning	Collaboration
anti-CD133 mAb (CMab-43; mouse IgG2a, kappa)	specific for CD133	FACS, WB, IHC, ADCC/CDC, antitumor activities		done	NIH
anti-CD133 mAb (CMab-44; mouse IgG1, kappa)	specific for CD133; detects AML	FACS, WB		done	NIH

Back to list

dog antigen for PIT	Character	Application	Gene cloning	Collaboration
anti-dog PDPN mAb (P38Bf; dog IgGB, kappa)	specific for dog PDPN	IHC, WB, FACS	done	NIH
anti-dog PDPN mAb (PMab-48; mouse IgG1, kappa)	specific for dog PDPN	IHC, WB, FACS	done	NIH
anti-dog EGFR mAb (E134Bf; dog IgGB, kappa)	specific for dog EGFR	IHC, WB, FACS	done	NIH
anti-dog PDPN mAb (H77Bf; dog IgGB, kappa)	specific for dog HER2	IHC, WB, FACS	done	NIH
anti-dog PDPN mAb (H2Mab-41; dog IgGB, kappa)	specific for dog HER2	FACS	done	NIH

Back to list

Antibody Bank(Kato's Lab; Tohoku University)

Antibody Bank
(Kato's Lab; Tohoku University)